Abbott Laboratories (ABT) director adds 263 stock equivalent units in Form 4 filing

Rhea-AI Filing Summary

Abbott Laboratories director reports routine stock-based compensation. A director of Abbott Laboratories reported a Form 4 transaction dated 12/31/2025 involving derivative securities in the form of stock equivalent units. The filing shows an acquisition of 263 stock equivalent units at a reference price of $125.29 per unit, each economically linked to one Abbott common share. Following this transaction, the director held 5,208 derivative securities in total, reported as directly owned.

According to the explanation, these units represent director fees credited to a stock equivalent unit account under a grantor trust, generally payable in cash at about age 65 or upon retirement from the board, and they earn the same return as if the fees were invested in Abbott shares. The balance also includes units accumulated through a dividend reinvestment feature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gonzalez Patricia Paola

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	(1)	12/31/2025		A		263		(1)	(1)	Common Shares	263	$125.29	5,208(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ Patricia Paola Gonzalez by Jessica H. Paik, Attorney-in-Fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abbott Laboratories (ABT) report in this Form 4?

The Form 4 reports that an Abbott Laboratories director acquired 263 stock equivalent units on 12/31/2025, each tied economically to one share of Abbott common stock.

How many Abbott-related derivative securities does the director hold after this transaction?

After the reported transaction, the director beneficially owned 5,208 derivative securities in the form of stock equivalent units, all reported as held in direct ownership.

What is the nature of the stock equivalent units reported by the Abbott (ABT) director?

The stock equivalent units represent director fees credited to a stock equivalent unit account under a grantor trust, generally paid in cash at about age 65 or upon retirement from the board, and they earn the same return as if the fees were invested in Abbott shares.

What price was used for the Abbott Laboratories stock equivalent unit transaction?

The acquisition of 263 stock equivalent units was reported at a reference price of $125.29 per unit, with each unit linked to one Abbott common share.

Does this Abbott (ABT) Form 4 involve dividend reinvestment?

Yes. The explanation states that the balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature, meaning some units arose from reinvested dividends rather than separate cash fees.

What is the reporting person’s relationship to Abbott Laboratories in this Form 4?

The reporting person is identified as a Director of Abbott Laboratories, and the Form 4 is filed by one reporting person, not a group.